Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
First Claim
1. A pharmaceutical composition for the treatment of diseases, disorders, or conditions comprising a therapeutic effective amount of human embryonic stem (hES) cells, derivatives of hES cells, or combinations thereof, wherein said hES cells, derivatives of hES cells, or combinations thereof are free from feeder cells, animal products, growth factors, leukemia inhibiting factor, fibroblast growth factor, vitamin supplements, membrane associated steel factor, soluble steel factor, and conditioned media, wherein the hES cells, derivatives of hES cells, or combinations thereof do not give rise to teratomas upon administration, wherein said hES cells, derivatives of hES cells, or combinations thereof are suspended in a pharmaceutically acceptable biocompatible solution, wherein said derivatives of hES cells are selected from the group consisting of hematopoietic stem cell progenitors, neuronal stem cell progenitors, a combination of hematopoietic stem cell progenitors and neuronal stem cell progenitors, mesenchymal stem cell progenitors, insulin producing stem cell progenitors, hepatocytic stem cell progenitors, cardiac stem cell progenitors, and epithelial stem cell progenitors, and wherein the composition contains trace amounts of a progestin and a β
- -human chorionic gonadotrophin (β
hCG) agonist.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.
-
Citations
33 Claims
-
1. A pharmaceutical composition for the treatment of diseases, disorders, or conditions comprising a therapeutic effective amount of human embryonic stem (hES) cells, derivatives of hES cells, or combinations thereof, wherein said hES cells, derivatives of hES cells, or combinations thereof are free from feeder cells, animal products, growth factors, leukemia inhibiting factor, fibroblast growth factor, vitamin supplements, membrane associated steel factor, soluble steel factor, and conditioned media, wherein the hES cells, derivatives of hES cells, or combinations thereof do not give rise to teratomas upon administration, wherein said hES cells, derivatives of hES cells, or combinations thereof are suspended in a pharmaceutically acceptable biocompatible solution, wherein said derivatives of hES cells are selected from the group consisting of hematopoietic stem cell progenitors, neuronal stem cell progenitors, a combination of hematopoietic stem cell progenitors and neuronal stem cell progenitors, mesenchymal stem cell progenitors, insulin producing stem cell progenitors, hepatocytic stem cell progenitors, cardiac stem cell progenitors, and epithelial stem cell progenitors, and wherein the composition contains trace amounts of a progestin and a β
- -human chorionic gonadotrophin (β
hCG) agonist. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
- -human chorionic gonadotrophin (β
-
25. A composition of matter comprising hES cells, derivatives of hES cells, or combinations thereof, wherein said hES cells, derivatives of hES cells, or combinations thereof are free from feeder cells, animal products, growth factors, leukemia inhibiting factor, fibroblast growth factor, vitamin supplements, membrane associated steel factor, soluble steel factor, and conditioned media, wherein the hES cells, derivatives of hES cells, or combinations thereof do not give rise to teratomas upon administration, wherein said hES cells, derivatives of hES cells, or combinations thereof are entrapped in a biocompatible structure or matrix, wherein the biocompatible structure or matrix is selectively permeable, wherein said hES cell derivatives are selected from the group consisting of hematopoietic stem cell progenitors, neuronal stem cell progenitors, a combination of hematopoietic stem cell progenitors and neuronal stem cell progenitors, mesenchymal stem cell progenitors, insulin producing stem cell progenitors, hepatocytic stem cell progenitors, cardiac stem cell progenitors, and epithelial stem cell progenitors, and wherein the composition contains trace amounts of a progestin and a β
- -human chorionic gonadotrophin (β
hCG) agonist. - View Dependent Claims (26, 27, 28, 29, 30, 31, 32, 33)
- -human chorionic gonadotrophin (β
Specification